曲马多治疗阿片类药物依赖的治疗经验:印度的一项前瞻性观察研究。

Q3 Medicine Journal of opioid management Pub Date : 2024-09-01 DOI:10.5055/jom.0898
Kirti Sharma, Prabhoo Dayal, Siddharth Sarkar, Sonali Jhanjee
{"title":"曲马多治疗阿片类药物依赖的治疗经验:印度的一项前瞻性观察研究。","authors":"Kirti Sharma, Prabhoo Dayal, Siddharth Sarkar, Sonali Jhanjee","doi":"10.5055/jom.0898","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Opioid use disorder (OUD) is a chronic relapsing disorder with significant mortality, morbidity, and public health challenges. In India, tramadol is frequently used for the treatment and management of OUDs.</p><p><strong>Methodology: </strong>A prospective observational study was performed to evaluate 3-month outcomes in outpatients with OUD on treatment with tramadol at a tertiary care addiction treatment facility in North India. One hundred and sixty newly registered patients fulfilling the inclusion and exclusion criteria were recruited and assessed on Maudsley Addiction Profile to evaluate changes in days and the amount of substance use and associated complications at 1-, 2-, and 3-month follow-up.</p><p><strong>Results: </strong>This study also showed a treatment retention rate of 14 percent with an abstinence rate of 34 percent at the end of the third month. The mean number of days of illicit opioid use in retained population decreased from 29.3 (±3.5) days from baseline to 12.5 (±10.9) days at 1 month, 5.0 (±7.2) days at 2 months, and 4.3 (±6.8) days at 3 months. Repeated measures analyses showed significant change in the days of illicit opioid use on treatment with tramadol over 3 months (p = 0.01).</p><p><strong>Conclusion: </strong>This study leads the way in showing tramadol as an important medication for use in OUDs to provide for maintenance therapy for longer durations. This has major implications in low- and middle-income countries, especially in Asia and Africa, where tramadol is more easily available.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"20 5","pages":"365-374"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic experience with tramadol for opioid dependence: A prospective observational study from India.\",\"authors\":\"Kirti Sharma, Prabhoo Dayal, Siddharth Sarkar, Sonali Jhanjee\",\"doi\":\"10.5055/jom.0898\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Opioid use disorder (OUD) is a chronic relapsing disorder with significant mortality, morbidity, and public health challenges. In India, tramadol is frequently used for the treatment and management of OUDs.</p><p><strong>Methodology: </strong>A prospective observational study was performed to evaluate 3-month outcomes in outpatients with OUD on treatment with tramadol at a tertiary care addiction treatment facility in North India. One hundred and sixty newly registered patients fulfilling the inclusion and exclusion criteria were recruited and assessed on Maudsley Addiction Profile to evaluate changes in days and the amount of substance use and associated complications at 1-, 2-, and 3-month follow-up.</p><p><strong>Results: </strong>This study also showed a treatment retention rate of 14 percent with an abstinence rate of 34 percent at the end of the third month. The mean number of days of illicit opioid use in retained population decreased from 29.3 (±3.5) days from baseline to 12.5 (±10.9) days at 1 month, 5.0 (±7.2) days at 2 months, and 4.3 (±6.8) days at 3 months. Repeated measures analyses showed significant change in the days of illicit opioid use on treatment with tramadol over 3 months (p = 0.01).</p><p><strong>Conclusion: </strong>This study leads the way in showing tramadol as an important medication for use in OUDs to provide for maintenance therapy for longer durations. This has major implications in low- and middle-income countries, especially in Asia and Africa, where tramadol is more easily available.</p>\",\"PeriodicalId\":16601,\"journal\":{\"name\":\"Journal of opioid management\",\"volume\":\"20 5\",\"pages\":\"365-374\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of opioid management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5055/jom.0898\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of opioid management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5055/jom.0898","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

导言:阿片类药物使用障碍(OUD)是一种慢性复发性疾病,具有严重的死亡率、发病率和公共卫生挑战。在印度,曲马多经常被用于治疗和管理阿片类药物使用障碍:一项前瞻性观察研究旨在评估印度北部一家三级戒毒治疗机构的 OUD 门诊病人接受曲马多治疗 3 个月后的疗效。研究人员招募了160名符合纳入和排除标准的新注册患者,并对他们进行了莫兹利成瘾特征评估,以评估他们在1个月、2个月和3个月的随访中使用药物的天数和数量以及相关并发症的变化:该研究还显示,治疗保持率为 14%,第三个月末的戒断率为 34%。保留人群使用非法阿片类药物的平均天数从基线的29.3(±3.5)天减少到1个月时的12.5(±10.9)天、2个月时的5.0(±7.2)天和3个月时的4.3(±6.8)天。重复测量分析显示,使用曲马多治疗3个月后,非法使用阿片类药物的天数发生了显著变化(p = 0.01):这项研究率先表明,曲马多是一种重要的药物,可用于治疗OUD,提供更长时间的维持治疗。这对中低收入国家具有重要意义,尤其是在曲马多更容易获得的亚洲和非洲。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Therapeutic experience with tramadol for opioid dependence: A prospective observational study from India.

Introduction: Opioid use disorder (OUD) is a chronic relapsing disorder with significant mortality, morbidity, and public health challenges. In India, tramadol is frequently used for the treatment and management of OUDs.

Methodology: A prospective observational study was performed to evaluate 3-month outcomes in outpatients with OUD on treatment with tramadol at a tertiary care addiction treatment facility in North India. One hundred and sixty newly registered patients fulfilling the inclusion and exclusion criteria were recruited and assessed on Maudsley Addiction Profile to evaluate changes in days and the amount of substance use and associated complications at 1-, 2-, and 3-month follow-up.

Results: This study also showed a treatment retention rate of 14 percent with an abstinence rate of 34 percent at the end of the third month. The mean number of days of illicit opioid use in retained population decreased from 29.3 (±3.5) days from baseline to 12.5 (±10.9) days at 1 month, 5.0 (±7.2) days at 2 months, and 4.3 (±6.8) days at 3 months. Repeated measures analyses showed significant change in the days of illicit opioid use on treatment with tramadol over 3 months (p = 0.01).

Conclusion: This study leads the way in showing tramadol as an important medication for use in OUDs to provide for maintenance therapy for longer durations. This has major implications in low- and middle-income countries, especially in Asia and Africa, where tramadol is more easily available.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of opioid management
Journal of opioid management Medicine-Anesthesiology and Pain Medicine
CiteScore
1.00
自引率
0.00%
发文量
54
期刊介绍: The Journal of Opioid Management deals with all aspects of opioids. From basic science, pre-clinical, clinical, abuse, compliance and addiction medicine, the journal provides and unbiased forum for researchers and clinicians to explore and manage the complexities of opioid prescription.
期刊最新文献
A pilot study to examine the opioid prescribing practices of medical residents. Buprenorphine: An anesthesia-centric review. Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients. Insurance coverage and consistent pricing is needed for over-the-counter naloxone. Naloxone coprescribing best practice advisory for patients at high risk for opioid-related adverse events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1